4th Annual
RNA Interference
June 19-21, 2006 at the Fairmont Hotel, San Francisco, California

Click here to register or go to https://commerce22.datapipe.com/chidb/2006/byg/reg.asp

Click here to download the Beyond Genome preliminary brochure


--------------------------------------------------------------------------------

Pre-Conference Events:
(separate registration required)
June 19th

Workshop: Optimizing RNAi Delivery
RNAi Off-Target Effects

Predicting Off-Target Effects in Genome-Wide Screening Programs
Dr. Irene Nooren, Associate Director, Bioinformatics, BioFocus

Widespread "Off-target" Silencing Mediated by Sequence Complementarity to the Seed Regions of siRNAs and shRNAs
Ms. Julja Burchard, Senior Research Associate, Biology, Rosetta Inpharmatics

RNAi Delivery in Vivo and in Vitro
Speakers to be Announced

Workshop: MicroRNA in Cancer

Lessons from the microRNA - Chronic Lymphocytic Leukemia Connection: New Paradigms in Molecular Oncology
Dr. George Calin, Research Assistant Professor, Molecular Virology, Immunology & Medical Genetics Department, Ohio State University

MicroRNAs as Novel Targets for Cancer Therapy
Dr. C. Frank Bennett, Senior Vice President, Research, Isis Pharmaceuticals

MicroRNAs in Cancer and Development
Dr. Aurora Esquela Kerscher, Postdoctoral Fellow, Frank Slack Lab, Department of Molecular, Cellular & Developmental Biology,
Yale University

MicroRNAs-based Diagnostics in Cancer A new approach
Prof. Zvi Bentwich, Chief Scientist, Rosetta Genomics LTD

Oncogenic microRNAs: The Gentle Balance Between Development and Disease
Dr. J. Michael Thomson, Postdoctoral Research Associate, The Hammond Lab, Dept. of Cell & Developmental Biology,
College of Medicine, University of North Carolina

MicroRNA profiling using qPCR arrays
Dr. Chris Raymond, Research Fellow, Merck Research Laboratories


--------------------------------------------------------------------------------

MAIN CONFERENCE
June 19-21
Preliminary Program

RNAi Screening for Target Discovery/Validation

Functionalizing the Druggable Genome Using Lentiviral-based RNAi
Dr. Anthony Orth, Gene Core Group Leader, Division of Genomics, Genomics Institute of the Novartis Research Foundation

Identification of New Oncology Drug Targets Using Loss of Function Genetic Screens of Focused and Genome
Scale siRNA Libraries
Dr. Steven R. Bartz, Research Fellow, Rosetta Inpharmatics, A wholly owned subsidiary of Merck & Co., Inc.

RNAi Screening of Kinases

Lentivirus-Mediated RNAi Screening
Dr. Richard Klinghoffer, Research Fellow, Cancer Biology, Rosetta Inpharmatics A wholly owned subsidiary of Merck & Co., Inc.

High-Throughput shRNA Screens for Essential Kinases Identify Novel Candidates for Cancer Drug Development
Dr. Dorre Grueneberg, Lecturer, Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School

RNAi in Animal Models

Viruses Designed to Combat Other Viruses: The Use of RNAi in Animal Models of Human Disease
Dr. Mark A. Kay, Professor, Departments of Pediatrics and Genetics, Stanford University

Transgenic RNA Interference in Mice
Dr. Pumin Zhang, Assistant Professor, Department of Molecular Physiology and Biophysics, Baylor College of Medicine

Title to be Announced
Dr. William L. Wishart, Senior Research Investigator, Genome and Proteome Sciences, Novartis Institutes for Biomedical Research

RNAi Therapeutics

RNAi Treatment for HIV Infection: Progress and Challenges
Dr. John Rossi, Professor & Chair, Division of Molecular Biology, Beckman Research Institute, City of Hope

Cancer Immunotherapy Using RNAi Technology
Dr. T.-C. Wu, Professor, Departments of Pathology, Oncology, Obstetrics and Gynecology and Molecular Microbiology and Immunology,
The Johns Hopkins Medical Institutions

siRNA Anti-angiogenesis Therapeutics Enhance Bevacizumab (Avastin) Treatment of Colorectal Cancer In Xenograft
Tumor Model
Dr. Patrick Lu, Executive Vice President, Intradigm Corp.